Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099940 | 0.83 | TSHR (0.39) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL24829622 | 0.82 | TSHR (0.38) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL43848 | 0.80 | TSHR (0.37) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL22644546 | 0.79 | SMN1; SMN2 (0.39) | TSHRSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL11507664 | 0.79 | TSHR (0.36) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL6277577 | 0.79 | SMN1; SMN2 (0.38) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL18932921 | 0.77 | ALDH1A1 (0.36) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL29335641 | 0.77 | — | — | |
| SCHEMBL19038331 | 0.76 | SMN1; SMN2 (0.43) | TSHRSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL17787230 | 0.75 | ALDH1A1 (0.39) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2023-05-25 | — | — | US | disclosed |
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | SUTURA THERAPEUTICS LTD (TC) | 2023-01-03 | — | — | US | disclosed |
| US-20220062431-A1 | COMPOUNDS COMPRISING STAPLED OR STITCHED PEPTIDES FOR IMPROVED DRUG DELIVERY | SUTURA THERAPEUTICS LTD (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20200353092-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LTD (TC) | 2020-11-12 | — | — | US | disclosed |
| WO-2019002875-A1 | COMPOUNDS COMPRISING STAPLED OR STITCHED PEPTIDES FOR IMPROVED DRUG DELIVERY | SUTURA THERAPEUTICS LTD (TC) | 2019-01-03 | — | — | WO | disclosed |
| WO-2017109494-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LTD (TC) | 2017-06-29 | — | — | WO | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-8361442-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-02 | — | — | US | disclosed |
| US-8030459-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | BPGM, TMPO, SLC7A1 | TSHR 3970/4885SMN1; SMN2 473/4885RAB9A 2796/4885 |
| US-20200353092-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | BPGM, TMPO, SLC7A1 | TSHR 3971/4885SMN1; SMN2 469/4885RAB9A 2789/4885 |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | TSHR 2129/4885SMN1; SMN2 3481/4885RAB9A 3407/4885 |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GNE, SORD, OGA | TSHR 3335/4885SMN1; SMN2 2497/4885RAB9A 4593/4885 |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | BPGM, PICALM, TMPO | TSHR 4158/4885SMN1; SMN2 623/4885RAB9A 3068/4885 |
| US-20220062431-A1 | COMPOUNDS COMPRISING STAPLED OR STITCHED PEPTIDES FOR IMPROVED DRUG DELIVERY | SPG11, SSBP1, SCAMP2 | TSHR 3370/4885SMN1; SMN2 943/4885RAB9A 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.